Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07282587 · ClinicalTrials.gov registry record · Phase 2
Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
A Phase 2 study of Advanced Pheochromocytoma and Paraganglioma and PCPG, sponsored by Jazz Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
- 9
- Study locations
NCT07282587 is a Phase 2 study of Advanced Pheochromocytoma and Paraganglioma and PCPG that is actively recruiting participants, run by Jazz Pharmaceuticals. The registered enrollment target is 90 participants. The trial reports 9 study locations across 8 states.
The verdict
NCT07282587, a Phase 2 study of Advanced Pheochromocytoma and Paraganglioma and PCPG, is actively recruiting participants, sponsored by Jazz Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
- 9
- Study locations
Study Summary
This is a two-stage Phase 2 trial evaluating the efficacy and safety of ONC206 in participants with Pheochromocytoma and Paraganglioma (PCPG).
Conditions Studied
Interventions
- DRUG ONC206
- DRUG ONC206: Dose 1
- DRUG ONC206: Dose 2
Study Locations (9)
California
- UCLA - Los Angeles
- Stanford - Palo Alto
Colorado
- U of Colorado - Aurora
Michigan
- U of Michigan - Ann Arbor
Minnesota
- Mayo-Rochester - Rochester
Missouri
- Washington University - St Louis
New York
- Columbia University Medical Center - New York
Pennsylvania
- PENN - Philadelphia
Utah
- UTAH - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-01-02 |
| Est. Completion | 2028-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07282587
The ClinicalTrials.gov registry entry for NCT07282587 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Advanced Pheochromocytoma and Paraganglioma appearing as the primary indexed condition, and to 3 interventions - of which ONC206 is the first listed.
NCT07282587 reports 9 study locations spanning 8 distinct geographic areas - top geographies include California, Colorado, Michigan.
Frequently Asked Questions
What is clinical trial NCT07282587 about?
NCT07282587 is a clinical study titled "Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma". This is a two-stage Phase 2 trial evaluating the efficacy and safety of ONC206 in participants with Pheochromocytoma and Paraganglioma (PCPG).
What is the current status of trial NCT07282587?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2026-01-02. Estimated completion is 2028-12-15.
What conditions does trial NCT07282587 study?
This clinical trial studies the following conditions: Advanced Pheochromocytoma and Paraganglioma, PCPG.
What interventions are being tested in trial NCT07282587?
The interventions under investigation include: ONC206 (DRUG), ONC206: Dose 1 (DRUG), ONC206: Dose 2 (DRUG).
Who is sponsoring clinical trial NCT07282587?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07282587 being conducted?
This trial has 9 study locations across California, Colorado, Michigan, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.